Catalent Supports Belgium-Based Cell and Gene Therapy Accelerator
Published on 05/07/2021
Brussels South Charleroi BioPark (BSCB) recently announced it has launched a Cell and Gene Therapy Accelerator program to de-risk early stage research and create the advanced therapy companies of the future. Open to academic, industry or independent researchers across Europe, the program consists of an intensive bootcamp, workshops and coaching, plus access to Université libre de Bruxelles (ULB) Open BioLab and state-of-the-art technology platforms. Find out more.
